Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first-line induction and maintenance regimens in extensive-stage small cell lung cancer.

Apar Kishor Ganti, Jeremy Snider, Jessie Yan et al. Jun 01, 2026 pp. 8093-8093 10.1200/jco.2026.44.16_suppl.8093

8093 Background: Both atezolizumab (atezo) and durvalumab (durva) are preferred first-line (1L) systemic treatment options...

Cognitive impairment during anti-EGFR targeted therapy in metastatic colorectal cancer patients.

Liubov Yu Vladimirova, Elvina Gevorkyan, Alexey Bobrov et al. Jun 01, 2026 pp. 12085-12085 10.1200/jco.2026.44.16_suppl.12085

12085 Background: Cognitive function is a critical determinant of psychosocial adaptation and quality of life in patients...

Oncological outcomes in post-menopausal women with Kallmann syndrome: A propensity-matched study from the Global Federated Health Network.

Sarah Eidbo, Maxim Barnett Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23061

e23061 Background: Kallmann syndrome, a rare form of hypogonadotropic hypogonadism with anosmia, is a condition primarily...

Real-world efficacy of immune checkpoint inhibitor rechallenge in patients with advanced esophageal squamous cell carcinoma: A retrospective study.

Qifan Zhang, Mengyuan Zhou, Siyuan Xing et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16046

e16046 Background: Immunotherapy combined with chemotherapy is the standard first-line (1L) treatment for advanced esophag...

Who really benefits from chemotherapy in high-risk localized soft tissue sarcoma? A virtual twin analysis of ISG-STS 1001.

Fahima Dossa, Dario Callegaro, Emanuela Palmerini et al. Jun 01, 2026 pp. 11573-11573 10.1200/jco.2026.44.16_suppl.11573

11573 Background: Randomized trials of perioperative chemotherapy in high-risk localized extremity/truncal soft tissue sar...

Impact of lung cancer screening in patients diagnosed with small cell lung cancer.

Paresh Kumar, Emmalee E. Kiser, Brook Marie Lobsiger et al. Jun 01, 2026 pp. 8102-8102 10.1200/jco.2026.44.16_suppl.8102

8102 Background: The advent of immunotherapy significantly improved overall survival (OS) for limited-stage SCLC (LS-SCLC)...

Impact of pre-existing cancer on short-term outcomes and mortality following left ventricular assist device implantation at urban teaching centers in the United States.

Ohikhuare Okun, Juma Rashid Bin Firos, FNU Anamika et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23056

e23056 Background: Cancer patients are at higher odds of various procedural complications. A recent study suggested a rise...

Integrated genomic and transcriptomic profiling of driver–pathway relationships in colorectal cancer.

Amish Vora, Sewanti Atul Limaye, Pritam Kataria et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15723

e15723 Background: Relationships between DNA driver alterations and downstream transcriptional pathway activation in color...

Trends in mortality, incidence, and disability-adjusted life years of laryngeal cancer in Pakistan from 1990 to 2023: A comprehensive analysis of the Global Burden of Disease study.

Muhammad Abbas Khokhar, Ammad Abid, Maria Qadri et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18010

e18010 Background: Laryngeal cancer remains a major cause of cancer-related mortality worldwide, particularly in low- and...

Racial disparities and nonconcordance with endocrine and HER2 therapy for breast cancer: A sequential mediation analysis of neighborhood deprivation and insurance status.

Jay Patel, Rafael Itinoche, Shubh Patel et al. Jun 01, 2026 pp. 1647-1647 10.1200/jco.2026.44.16_suppl.1647

1647 Background: Racial disparities in breast cancer treatment persist, but the mechanisms driving inequities may differ b...

Clinical performance and readiness of artificial intelligence models for predicting immune-related adverse events in patients receiving immune checkpoint inhibitors: A systematic review.

Swathi Priya Cherukuri, Mansha Gupta, Abhijith Vemulapalli et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13683

e13683 Background: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but are frequently complicated by...

Closing the gap in germline testing in patients with cancer through a clinic-based awareness initiative: From booth to patient's agenda.

Luisina Ines Bruno, Guillermo Alberto, Agostina Tardivo et al. Jun 01, 2026 pp. 1603-1603 10.1200/jco.2026.44.16_suppl.1603

1603 Background: Germline genetic testing (GT) is a standard of care for a broad range of patients (pts) diagnosed with ca...

Major adverse cardiovascular events during elective chemotherapy admissions: Incidence, predictors, and in-hospital outcomes.

Zeina Assaf, Anas Alahmad, Jasmeet Sandhu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24020

e24020 Background: Cardiovascular complications represent a major source of morbidity among patients receiving systemic ch...

Prophylactic vs reactive PEG tube placement in early-stage head and neck (H&N) cancer treated with curative-intent radiotherapy: Balancing benefit and burden in real-world practice.

Fayaz Aijaz Ahmed Khan, Andrew Chang, Rebecca Calabrese Jun 01, 2026 pp. 12150-12150 10.1200/jco.2026.44.16_suppl.12150

12150 Background: Timing of Percutaneous Endoscopic Gastrostomy (PEG) placement during curative-intent radiotherapy for H&...

Comorbidities as independent predictors of mortality in lung cancer: A real-world multivariate analysis from a Latin American tertiary center with integrated molecular profiling.

Henry Vargas, Zamira Fernanda Gomez Giraldo, Maria Paula Uchima-Vera et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20093

e20093 Background: Lung cancer patients frequently present with multiple comorbidities that may significantly influence su...

Education, income, treatment, and survival: A retrospective cohort study of patients with breast cancer in Sao Paulo, Brazil.

Sydney Johnson, Haydee Cristina Verduzco-Aguirre, Fernanda Malucelli Favorito et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13620

e13620 Background: Socioeconomic factors influence breast cancer stage at diagnosis, access to treatment, and survival, ye...

Impact of age on immune-related toxicities and survival in non–small cell lung cancer treated with immune checkpoint inhibitors: A multicenter retrospective study.

Shruti Shah, Deevyashali Parekh, Safa Saadat Afridi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20641

e20641 Background: Immune checkpoint inhibitors (ICIs) are a cornerstone of therapy for non-small cell lung cancer (NSCLC)...

Caregiver professional employment and its impact on glioblastoma patient survival: Results from two prospective studies.

Vincenzo Di Nunno, Alicia Tosoni, Isacco Desideri et al. Jun 01, 2026 pp. 2050-2050 10.1200/jco.2026.44.16_suppl.2050

2050 Background: Caregiver burden is a crucial factor to consider in the diagnosis and care of patients with glioblastoma...

Risk of lung cancer among patients with idiopathic interstitial lung disease: A cohort study using All of Us research program data.

Geraldine Kordai Mould, Marie Thearle, Rasheed Olaide Awodun et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20089

e20089 Background: Interstitial lung disease (ILD), a collection of heterogeneous conditions characterized by lung inflamm...

Real-world quality outcomes following implementation of a comprehensive care program in community oncology practice in western India.

Pradip Kendre, Udip Maheshwari, Disha Morzaria et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13575

e13575 Background: Malnutrition, psychosocial distress & impaired quality of life (QoL) adversely affect treatment tol...

A phase 1, multicenter, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SBO-154 in subjects with advanced solid tumors.

Charlotte Rose Lemech, Joe Wei, Sant P. Chawla et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3161

TPS3161 Background: Mucin 1 (MUC1) is a transmembrane glycoprotein overexpressed in advanced epithelial malignancies, wher...

Effect of frailty measures on overall survival in prostate cancer: A systematic review and meta-analysis.

Nicole Sequeira, Ursula Medeiros Araujo de Matos, Pedro Luiz Lage Bodour Danielian et al. Jun 01, 2026 pp. 5077-5077 10.1200/jco.2026.44.16_suppl.5077

5077 Background: Prostate cancer at all stages is associated with a favorable prognosis and treatment is generally well to...

Association of chemotherapy with survival in node-positive penile squamous cell carcinoma stratified by nodal burden: A National Cancer Database analysis.

Shreyas Kalantri, Tyler Jones, Maiying Kong et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17033

e17033 Background: Node-positive penile squamous cell carcinoma (PSCC) carries a poor prognosis, yet the survival benefit...

Biomarker use in subgroup analysis versus enrichment trial design as a predictor of oncology trial success.

Sahil Gupta, Sumeet Patiyal, Eytan Ruppin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23122

e23122 Background: Biomarkers are widely used in oncology clinical trials for patient stratification and endpoint definiti...

Incidence, severity, and management of severe adverse events in first-line (1L) treatments for metastatic pancreatic ductal adenocarcinoma (mPDAC): A retrospective observational study.

Robert R. McWilliams, Omar Almudallal, Seema Meloni et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16377

e16377 Background: 1L systemic treatment of mPDAC can lead to severe adverse events (AEs). To contextualize the safety pro...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page